BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;95:281-95. [PMID: 30665569 DOI: 10.1016/j.kint.2018.11.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 31.5] [Reference Citation Analysis]
Number Citing Articles
1 Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344-58. [PMID: 31180031 DOI: 10.1016/S0140-6736(19)30546-X] [Cited by in Crossref: 115] [Cited by in F6Publishing: 62] [Article Influence: 38.3] [Reference Citation Analysis]
2 Yu F, Li G, Hao W, Hu W. Hepatitis B Virus-Related Glomerulonephritis with Positive and Negative Serum HBsAg: Different Clinicopathologic Characteristics of Two Clinical Subtypes. Int J Gen Med 2021;14:3069-77. [PMID: 34234535 DOI: 10.2147/IJGM.S318087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Said SM, Leung N, Alexander MP, Cornell LD, Fidler ME, Grande JP, Herrera LH, Sethi S, Zhang P, Nasr SH. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney Int 2020;98:498-504. [PMID: 32622524 DOI: 10.1016/j.kint.2020.02.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y; Japan Nephrotic Syndrome Cohort Study investigators. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study. J Nephrol 2022. [PMID: 35366214 DOI: 10.1007/s40620-022-01279-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
6 Roccatello D, Sciascia S, Fenoglio R, Rossi D. A new challenge for lupus nephritis management: Induction therapy without immunosuppressive maintenance regimen. Autoimmun Rev 2021;20:102844. [PMID: 33971336 DOI: 10.1016/j.autrev.2021.102844] [Reference Citation Analysis]
7 Wenderfer SE, Chang J, Hicks MJ. Approach to Classification and Management of Childhood-Onset Lupus Nephritis. Curr Pediatr Rep 2020;8:26-35. [DOI: 10.1007/s40124-020-00207-8] [Reference Citation Analysis]
8 Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev 2020;19:102671. [PMID: 32942039 DOI: 10.1016/j.autrev.2020.102671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Huang L, Shen C, Zhong Y, Ooi JD, Zhou YO, Chen JB, Wu T, Meng T, Xiao Z, Lin W, Ao X, Xiao X, Zhou Q, Xiao P. Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis. Clin Exp Med 2020;20:199-206. [PMID: 32078076 DOI: 10.1007/s10238-020-00614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Mejía-Vilet JM, Martín-Nares E, Cano-Verduzco ML, Pérez-Arias AA, Sedano-Montoya MA, Hinojosa-Azaola A. Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage. Clin Rheumatol 2020;39:1935-43. [PMID: 31970548 DOI: 10.1007/s10067-020-04936-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Claudel SE, Tucker BM, Kleven DT, Pirkle JL Jr, Murea M. Narrative Review of Hypercoagulability in Small-Vessel Vasculitis. Kidney Int Rep 2020;5:586-99. [PMID: 32405580 DOI: 10.1016/j.ekir.2019.12.018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Semin Immunol 2019;45:101331. [PMID: 31711769 DOI: 10.1016/j.smim.2019.101331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Prendecki M, Mcadoo SP, Pusey CD. Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis? Curr Treat Options in Rheum 2020;6:313-24. [DOI: 10.1007/s40674-020-00161-y] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Moret L, Ganea A, Dao M, Hummel A, Knebelman B, Subra JF, Noble J, Mariat C, Jourde-Chiche N, Toure F, Garrouste C, Laurent C, Adeline L, Delmas Y, Cez A, Fritz O, Mousson C, Pouteau LM, Moranne O, Halimi JM, Audard V. Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. Kidney Int Rep 2021;6:2134-43. [PMID: 34386662 DOI: 10.1016/j.ekir.2021.04.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kopp JB, Anders HJ, Susztak K, Podestà MA, Remuzzi G, Hildebrandt F, Romagnani P. Podocytopathies. Nat Rev Dis Primers 2020;6:68. [PMID: 32792490 DOI: 10.1038/s41572-020-0196-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
16 Ozeki T, Maruyama S, Nagata M, Shimizu A, Sugiyama H, Sato H, Yokoyama H; Committee for Renal Biopsy and Disease Registry of the Japanese Society of Nephrology. The revised version 2018 of the nationwide web-based registry system for kidney diseases in Japan: Japan Renal Biopsy Registry and Japan Kidney Disease Registry. Clin Exp Nephrol 2020;24:1058-68. [PMID: 32761468 DOI: 10.1007/s10157-020-01932-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ke G, Xie Z, Xiao J, Zhang Y, Hu Y, Li B, Jiang N, Chen X, Liu S, Shi W. Comparison of 6 equations for estimating glomerular filtration rate in a Chinese benign hypertensive nephrosclerosis population. Medicine (Baltimore) 2021;100:e28318. [PMID: 34941129 DOI: 10.1097/MD.0000000000028318] [Reference Citation Analysis]
18 Lu H, Xiao L, Song M, Liu X, Wang F. Acute kidney injury in patients with primary nephrotic syndrome: influencing factors and coping strategies. BMC Nephrol 2022;23. [DOI: 10.1186/s12882-022-02720-y] [Reference Citation Analysis]
19 Kitada M, Koya D. Proposal of classification of "chronic kidney disease (CKD) with diabetes" in clinical setting. Diabetol Int 2019;10:180-2. [PMID: 31275783 DOI: 10.1007/s13340-019-00396-8] [Reference Citation Analysis]
20 Basu B, Angeletti A, Islam B, Ghiggeri GM. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are? Front Immunol 2022;13:805697. [DOI: 10.3389/fimmu.2022.805697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zanoni F, Khairallah P, Kiryluk K, Batal I. Glomerular Diseases of the Kidney Allograft: Toward a Precision Medicine Approach. Seminars in Nephrology 2022;42:29-43. [DOI: 10.1016/j.semnephrol.2022.01.005] [Reference Citation Analysis]
22 Huang L, Zhong Y, Ooi JD, Zhou YO, Zuo X, Luo H, Chen JB, Wu T, Yang Y, Meng T, Xiao Z, Lin W, Ao X, Xiao X, Zhou Q, Xiao P. The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis. Int Immunopharmacol 2019;76:105883. [PMID: 31536905 DOI: 10.1016/j.intimp.2019.105883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Ramachandran R, Kumar V, Bharati J, Rovin B, Nada R, Kumar V, Rathi M, Jha V, Gupta KL, Kohli HS. Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy. Kidney Int Rep 2021;6:2653-60. [PMID: 34622104 DOI: 10.1016/j.ekir.2021.07.028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ohkubo N, Iwata S, Nakano K, Miyagawa I, Hanami K, Fukuyo S, Miyazaki Y, Kawabe A, Nakayamada S, Tanaka Y. Efficacy and Safety of High-Dose of Mycophenolate Mofetil Compared With Cyclophosphamide Pulse Therapy as Induction Therapy in Japanese Patients with Proliferative Lupus Nephritis. Mod Rheumatol 2021:roab113. [PMID: 34915579 DOI: 10.1093/mr/roab113] [Reference Citation Analysis]
26 Pannu AK, Golla R, Kumari S, Suri V, Gupta P, Kumar R. Aetiology of pyrexia of unknown origin in north India. Trop Doct 2021;51:34-40. [PMID: 32807027 DOI: 10.1177/0049475520947907] [Reference Citation Analysis]
27 Trutin I, Oletić L, Galešić Ljubanović D, Turudić D, Milošević D. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY. Acta Clin Croat 2021;60:141-5. [PMID: 34588735 DOI: 10.20471/acc.2021.60.01.21] [Reference Citation Analysis]
28 Gilbert M, Goilav B, Hsu JJ, Nietert PJ, Meidan E, Chua A, Ardoin SP, Wenderfer SE, von Scheven E, Ruth NM; Pediatric Nephrology and Rheumatology Collaborative Group, the Childhood Arthritis and Rheumatology Research Alliance, and the American Society for Pediatric Nephrology. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online J 2021;19:137. [PMID: 34461932 DOI: 10.1186/s12969-021-00627-w] [Reference Citation Analysis]
29 Moran SM, Barbour S, Dipchand C, Garland JS, Hladunewich M, Jauhal A, Kappel JE, Levin A, Pandeya S, Reich HN, Thanabalasingam S, Thomas D, Ma JC, White C. Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Can J Kidney Health Dis 2020;7:2054358120968955. [PMID: 33294202 DOI: 10.1177/2054358120968955] [Reference Citation Analysis]
30 Kalantar-Zadeh K, Baker CL, Copley JB, Levy DI, Berasi S, Tamimi N, Alvir J, Udani SM. A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States. Kidney Int Rep 2021;6:2679-88. [PMID: 34622107 DOI: 10.1016/j.ekir.2021.07.030] [Reference Citation Analysis]
31 Caster DJ, Powell DW. Utilization of Biomarkers in Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:351-9. [PMID: 31733719 DOI: 10.1053/j.ackd.2019.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
32 Wang Y, Wu CJ, Du Y, Liu YQ, Cai JR, Wu XQ, Hu SQ. SIRT2 tyrosine nitration by peroxynitrite in response to renal ischemia/reperfusion injury. Free Radic Res 2022;:1-15. [PMID: 34979841 DOI: 10.1080/10715762.2021.2024529] [Reference Citation Analysis]
33 Roccatello D, Sciascia S, Naretto C, Alpa M, Fenoglio R, Ferro M, Quattrocchio G, Rubini E, Rahbani E, Rossi D. A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. Kidney Int Rep 2021;6:1081-7. [PMID: 33912758 DOI: 10.1016/j.ekir.2021.01.027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Ayoub I, Cassol C, Almaani S, Rovin B, Parikh SV. The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. Adv Chronic Kidney Dis 2019;26:360-8. [PMID: 31733720 DOI: 10.1053/j.ackd.2019.08.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
35 Lin B, Liu J, Zhang Y, Wu Y, Chen S, Bai Y, Liu Q, Qin X. Urinary peptidomics reveals proteases involved in idiopathic membranous nephropathy. BMC Genomics 2021;22:852. [PMID: 34819020 DOI: 10.1186/s12864-021-08155-3] [Reference Citation Analysis]
36 Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis. Clin J Am Soc Nephrol 2020;15:1740-8. [PMID: 33203735 DOI: 10.2215/CJN.07210520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Pyo JY, Lee LE, Ahn SS, Song JJ, Park YB, Lee SW. Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis. Medicine (Baltimore) 2021;100:e26956. [PMID: 34449460 DOI: 10.1097/MD.0000000000026956] [Reference Citation Analysis]
38 Collins KS, Cheng YH, Ferreira RM, Gao H, Dollins MD, Janosevic D, Khan NA, White C, Dagher PC, Eadon MT. Interindividual Variability in Lymphocyte Stimulation and Transcriptomic Response Predicts Mycophenolic Acid Sensitivity in Healthy Volunteers. Clin Transl Sci 2020;13:1137-49. [PMID: 32415749 DOI: 10.1111/cts.12795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Shropshire S, Johnson T, Olver C. Platelet aggregometry testing during aspirin or clopidogrel treatment and measurement of clopidogrel metabolite concentrations in dogs with protein-losing nephropathy. J Vet Intern Med 2020;34:710-8. [PMID: 31981378 DOI: 10.1111/jvim.15694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Dos Santos M, Veronese FV, Moresco RN. Uric acid and kidney damage in systemic lupus erythematosus. Clin Chim Acta 2020;508:197-205. [PMID: 32428504 DOI: 10.1016/j.cca.2020.05.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Rodriguez-Ballestas E, Reid-Adam J. Nephrotic Syndrome. Pediatr Rev 2022;43:87-99. [PMID: 35102405 DOI: 10.1542/pir.2020-001230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Bryant C, Rask G, Waller AP, Webb A, Galdino-pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FA, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience 2022;25:104001. [DOI: 10.1016/j.isci.2022.104001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zheng Z, Zhang H, Peng X, Zhang C, Xing C, Xu G, Fu P, Ni Z, Chen J, Xu Z, Zhao MH, Li S, Huang X, Miao L, Chen X, Liu B, He Y, Li J, Liu L, Kadeerbai H, Liu Z, Liu Z. Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial. JAMA Netw Open 2022;5:e224492. [PMID: 35353167 DOI: 10.1001/jamanetworkopen.2022.4492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 da Mata GF, Fernandes DE, Luciano EP, Sales GTM, Riguetti MTP, Kirsztajn GM. Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV. J Venom Anim Toxins Incl Trop Dis 2021;27:e20200154. [PMID: 34381495 DOI: 10.1590/1678-9199-JVATITD-2020-0154] [Reference Citation Analysis]
45 Yazılıtaş F, Kargın Çakıcı E, Kurt Şükür ED, Can G, Güngör T, Orhan D, Bülbül M. C3 glomerulopathy: experience of a pediatric nephrology center. Acta Clin Belg 2021;76:253-7. [PMID: 31914901 DOI: 10.1080/17843286.2020.1713450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pesce F, Stea ED, Rossini M, Fiorentino M, Piancone F, Infante B, Stallone G, Castellano G, Gesualdo L. Glomerulonephritis in AKI: From Pathogenesis to Therapeutic Intervention. Front Med (Lausanne) 2020;7:582272. [PMID: 33738291 DOI: 10.3389/fmed.2020.582272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Wang Y, Wu XQ, Cai JR, Ji HX, Xu T. SIRT7 silencing by miR-152-3p confers cell apoptosis and renal functional impairment induced by renal ischaemia/reperfusion injury. Int Urol Nephrol 2022. [PMID: 35941302 DOI: 10.1007/s11255-022-03330-1] [Reference Citation Analysis]
48 Wu X, Zhong Y, Meng T, Ooi JD, Eggenhuizen PJ, Tang R, Nie W, Xiao X, Sun J, Ao X, Zhang H. Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis. Front Med (Lausanne) 2021;8:775586. [PMID: 35118086 DOI: 10.3389/fmed.2021.775586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Garantziotis P, Doumas SAP, Boletis I, Frangou E. Gene Expression as a Guide to the Development of Novel Therapies in Primary Glomerular Diseases. J Clin Med 2021;10:2262. [PMID: 34073694 DOI: 10.3390/jcm10112262] [Reference Citation Analysis]
50 Ralli M, Campo F, Angeletti D, Minni A, Artico M, Greco A, Polimeni A, de Vincentiis M. Pathophysiology and therapy of systemic vasculitides. EXCLI J 2020;19:817-54. [PMID: 32665772 DOI: 10.17179/excli2020-1512] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
51 An Y, Zhang H, Liu Z. Individualizing Therapy in Lupus Nephritis. Kidney Int Rep 2019;4:1366-72. [PMID: 31701046 DOI: 10.1016/j.ekir.2019.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Zhang L, Zhang K, Dong W, Li R, Huang R, Zhang H, Shi W, Liu S, Li Z, Chen Y, Ye Z, Liang X, Yu X. Raised Plasma Levels of Asymmetric Dimethylarginine Are Associated with Pathological Type and Predict the Therapeutic Effect in Lupus Nephritis Patients Treated with Cyclophosphamide. Kidney Dis (Basel) 2020;6:355-63. [PMID: 33490115 DOI: 10.1159/000509767] [Reference Citation Analysis]
53 Tan J, Xu Y, Jiang Z, Pei G, Tang Y, Tan L, Zhong Z, Tarun P, Qin W. Global Glomerulosclerosis and Segmental Glomerulosclerosis Could Serve as Effective Markers for Prognosis and Treatment of IgA Vasculitis With Nephritis. Front Med (Lausanne) 2020;7:588031. [PMID: 33195349 DOI: 10.3389/fmed.2020.588031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
54 Meuleman MS, Guilmin-Crépon S, Hummel A, Daugas E, Dumas A, Leye F, Dantal J, Rigothier C, Provot F, Chauveau D, Burtey S, Hertig A, Dahan K, Durrbach A, Dossier C, Karras A, Guerrot D, Esnault V, Rémy P, Massy ZA, Tostivint I, Morin MP, Zaoui P, Fritz O, Le Quintrec M, Wynckel A, Bourmaud A, Boyer O, Sahali D, Alberti C, Audard V, Mellerio H. Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. J Nephrol 2021. [PMID: 34224090 DOI: 10.1007/s40620-021-01111-0] [Reference Citation Analysis]
55 Yin P, Li J, Wen Q, Qiu Y, Liang W, Wang J, Yu J, Zhong Z, Yang X, Yu X, Ye Q, Huang F. Infection-related hospitalization after intensive immunosuppressive therapy among lupus nephritis and ANCA glomerulonephritis patients. Ren Fail 2020;42:474-82. [PMID: 32406300 DOI: 10.1080/0886022X.2020.1763400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Cutrim ÉMM, Neves PDMDM, Campos MAG, Wanderley DC, Teixeira-júnior AAL, Muniz MPR, Ladchumananandasivam FR, Gomes OV, Vasco RFV, Brito DJDA, Lages JS, Salgado-filho N, Guedes FL, de Almeida JB, Magalhães M, Araújo SDA, Silva GEB. Collapsing Glomerulopathy: A Review by the Collapsing Brazilian Consortium. Front Med 2022;9:846173. [DOI: 10.3389/fmed.2022.846173] [Reference Citation Analysis]
57 Fenoglio R, Sciascia S, Baldovino S, Roccatello D. Acute kidney injury associated with glomerular diseases: . Current Opinion in Critical Care 2019;25:573-9. [DOI: 10.1097/mcc.0000000000000675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
58 Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, Yin H, Chen J, Pu J, Peng Z, Peng W, Li X, Xiao X, Zhou Q, Zhong Y, Xiao P. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med 2019;18:3984-90. [PMID: 31611938 DOI: 10.3892/etm.2019.8023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
59 Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, Caudwell V, Chiche L, Couzi L, Daniel L, Deligny C, Dussol B, Faguer S, Gobert P, Gondran G, Huart A, Hummel A, Kalbacher E, Karras A, Lambert M, Le Guern V, Lebourg L, Loubière S, Maillard-Lefebvre H, Maurier F, Pha M, Queyrel V, Remy P, Sarrot-Reynauld F, Verhelst D, Hachulla E, Amoura Z, Daugas E; WIN-Lupus study group. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis 2022:annrheumdis-2022-222435. [PMID: 35725295 DOI: 10.1136/annrheumdis-2022-222435] [Reference Citation Analysis]
60 Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus Podocytopathy: An Overview. Adv Chronic Kidney Dis 2019;26:369-75. [PMID: 31733721 DOI: 10.1053/j.ackd.2019.08.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
61 Xiang X, Qiu SY, Wang M. Mycophenolate Mofetil in the Treatment of Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children: A Meta-Analysis. Front Pediatr 2021;9:671434. [PMID: 34211944 DOI: 10.3389/fped.2021.671434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Shabaka A, Landaluce-triska E, Sánchez-álvarez JE, Fernández-juárez G. Changing trends in presentation and indications of biopsy in lupus nephritis: data from the Spanish Registry of Glomerulonephritis. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab236] [Reference Citation Analysis]
63 Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Sinha A, Bagga A; Expert Group of Indian Society of Pediatric Nephrology. Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome. Indian Pediatr 2021;58:650-66. [DOI: 10.1007/s13312-021-2262-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
64 Trimarchi H. Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies. Kidney Dis (Basel) 2020;6:324-9. [PMID: 33490112 DOI: 10.1159/000507997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 De Mutiis C, Wenderfer SE, Orjuela A, Bagga A, Basu B, Sar T, Aggarwal A, Jain A, Yap HK, Ito S, Ohnishi A, Iwata N, Kasapcopur O, Laurent A, Mastrangelo A, Ogura M, Shima Y, Rianthavorn P, Silva CA, Trindade V, Dormi A, Tullus K. Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology (Oxford) 2021:keab746. [PMID: 34626102 DOI: 10.1093/rheumatology/keab746] [Reference Citation Analysis]
66 Strufaldi FL, Menezes Neves PDMM, Dias CB, Yu L, Woronik V, Cavalcante LB, Malheiros DMAC, Jorge LB. Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis. J Nephrol 2021;34:1147-56. [PMID: 33570723 DOI: 10.1007/s40620-020-00938-3] [Reference Citation Analysis]
67 Mejía-Vilet JM, Romero-Díaz J. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34392746 DOI: 10.1080/1744666X.2021.1967747] [Reference Citation Analysis]